# Atebimetinib PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/atebimetinib

> The next catalyst for atebimetinib, sponsored by Immuneering Corp (IMRX), is its topline data readout, 1H 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, year only, exact day, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What is the next FDA catalyst for atebimetinib?

The next catalyst for atebimetinib, sponsored by Immuneering Corp (IMRX), is its topline data readout, 1H 2027. Press release filed with the SEC (EX-99): "We now plan to provide an update on topline data from the atebimetinib + mGnP arm of that trial in the first half of 2027." [Calendar and source filings](https://sec-api.dev/pdufa/atebimetinib)

Source: Press release filed with the SEC (EX-99), accession 0001790340-26-000095, https://www.sec.gov/Archives/edgar/data/1790340/000179034026000095/imrx-20261029xexx991.htm (retrieved 2026-11-12). Last confirmed 2026-10-29. Cite: https://sec-api.dev/pdufa/atebimetinib#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | atebimetinib |
| Codes |  |
| Sponsor | Immuneering Corp (IMRX) https://sec-api.dev/companies/imrx/catalysts |
| Indications | with advanced or metastatic solid tumors, Pancreatic Cancer |
| Modality | small_molecule |
| FDA designations | fast track, orphan |

## Timeline

### Sep 2022: trial start

- Status: completed. Date confidence: month. Stage: 1/2. Indication: with advanced or metastatic solid tumors.
- First seen 2025-08-13, last confirmed 2025-11-12.
- SEC Form 10-Q (accession 0001790340-25-000135): "In September 2022, the FDA cleared our IND application for atebimetinib and, in November 2022, we commenced dosing in our Phase 1/2a clinical trial of atebimetinib for the potential treatment of patients with advanced or metastatic solid tumors." https://www.sec.gov/Archives/edgar/data/1790340/000179034025000135/imrx-20250930.htm
- SEC Form 10-Q (accession 0001790340-25-000104): "In September 2022, the FDA cleared our IND application for atebimetinib and, in November 2022, we commenced dosing in our Phase 1/2a clinical trial of atebimetinib for the potential treatment of patients with advanced or metastatic solid tumors." https://www.sec.gov/Archives/edgar/data/1790340/000179034025000104/imrx-20250630.htm

### Jun 2025: interim data readout

- Status: completed, positive. Date confidence: month. Stage: 2.
- First seen 2025-08-13, last confirmed 2025-08-13.
- SEC Form 10-Q (accession 0001790340-25-000104): "In June 2025, we announced positive interim data from our ongoing Phase 2a clinical trial arm evaluating atebimetinib in combination with modified Gemcitabine/nab-Paclitaxel ("mGnP") in first-line pancreatic cancer patients (the "mGnP Arm")." https://www.sec.gov/Archives/edgar/data/1790340/000179034025000104/imrx-20250630.htm

### Jan 2026: interim data readout

- Status: completed, positive. Date confidence: month. Stage: 2.
- First seen 2026-03-06, last confirmed 2026-03-06.
- SEC Form 10-K (accession 0001790340-26-000042): "In January 2026, we announced further updated positive interim data from our ongoing Phase 2a clinical trial arm evaluating atebimetinib in combination with mGnP in first-line pancreatic cancer patients." https://www.sec.gov/Archives/edgar/data/1790340/000179034026000042/imrx-20251231.htm

### 2026: trial start

- Status: scheduled. Date confidence: year. Stage: 2.
- First seen 2025-06-17, last confirmed 2025-08-13.
- SEC Form 8-K (accession 0001790340-25-000077): "Also on June 17, 2025, the Company announced that additional data from the Phase 2a portion of the Company's atebimetinib Phase 1/2a trial was expected in the fourth quarter of 2025, and that the Company planned, pending regulatory feedback expected in the fourth quarter of 2025, to initiate a pivotal trial evaluating atebimetinib in combination with mGnP in first-line pancreatic cancer patients in 2026, and to initiate additional clinical trial combination arms evaluating atebimetinib also in 2026." https://www.sec.gov/Archives/edgar/data/1790340/000179034025000077/imrx-20250617.htm
- Press release filed with the SEC (EX-99) (accession 0001790340-25-000102): "Subject to regulatory feedback, the company plans to initiate a pivotal trial of atebimetinib in combination with mGnP in first-line pancreatic cancer patients in 2026." https://www.sec.gov/Archives/edgar/data/1790340/000179034025000102/imrx-20250813xexx991.htm
- SEC Form 10-Q (accession 0001790340-25-000104): "Pending regulatory feedback, we plan to initiate a registrational, randomized controlled trial of atebimetinib in combination with mGnP in first-line pancreatic cancer in 2026." https://www.sec.gov/Archives/edgar/data/1790340/000179034025000104/imrx-20250630.htm

### August 5, 2026: trial start

- Status: completed. Date confidence: exact. Stage: 3.
- First seen 2026-08-05, last confirmed 2026-08-05.
- Press release filed with the SEC (EX-99) (accession 0001790340-26-000088): "In June, Immuneering announced it had dosed the first patient in MAPKeeper 301, a global, randomized, open-label pivotal Phase 3 clinical trial evaluating atebimetinib + mGnP in first-line metastatic pancreatic cancer patients." https://www.sec.gov/Archives/edgar/data/1790340/000179034026000088/imrx-20260805xexx991.htm

### 1H 2027: topline data readout

- Status: scheduled. Date confidence: half. Stage: 2.
- First seen 2026-10-29, last confirmed 2026-10-29.
- Press release filed with the SEC (EX-99) (accession 0001790340-26-000095): "We now plan to provide an update on topline data from the atebimetinib + mGnP arm of that trial in the first half of 2027." https://www.sec.gov/Archives/edgar/data/1790340/000179034026000095/imrx-20261029xexx991.htm
- Press release filed with the SEC (EX-99) (accession 0001790340-26-000095): "•Phase 2 Pancreatic Cancer Trial Extended; Topline Data Update Expected in 1H 2027." https://www.sec.gov/Archives/edgar/data/1790340/000179034026000095/imrx-20261029xexx991.htm

### late 2027: interim data readout

- Status: scheduled. Date confidence: half. Stage: 2.
- First seen 2026-06-01, last confirmed 2026-10-29.
- SEC Form 8-K (accession 0001790340-26-000059): "•In the second half of 2026, dosing the first patient in a clinical trial of atebimetinib in combination with Libtayo® in non-small cell lung cancer patients, with a preliminary data readout expected in late-2027." https://www.sec.gov/Archives/edgar/data/1790340/000179034026000059/imrx-20260601.htm
- SEC Form 10-Q (accession 0001790340-26-000097): "•in the fourth quarter of 2026, dosing the first patient in a clinical trial of atebimetinib in combination with Libtayo® in non-small cell lung cancer patients, with a preliminary data readout expected in late-2027;" https://www.sec.gov/Archives/edgar/data/1790340/000179034026000097/imrx-20260930.htm
- SEC Form 10-Q (accession 0001790340-26-000091): "•in the second half of 2026, dosing the first patient in a clinical trial of atebimetinib in combination with Libtayo® in non-small cell lung cancer patients, with a preliminary data readout expected in late-2027;" https://www.sec.gov/Archives/edgar/data/1790340/000179034026000091/imrx-20260630.htm
- Press release filed with the SEC (EX-99) (accession 0001790340-26-000095): "•Late-2027: Preliminary data readout expected from Phase 2 trial of atebimetinib + anti-PD-1 (cemiplimab) in lung cancer." https://www.sec.gov/Archives/edgar/data/1790340/000179034026000095/imrx-20261029xexx991.htm

### June 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Pancreatic Cancer; Pancreatic Cancer Metastatic; PDAC.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07562152 (Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor Immuneering Corporation." https://clinicaltrials.gov/study/NCT07562152

### Jun to Sep 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Pancreatic Cancer; Pancreatic Cancer Metastatic; PDAC.
- First seen 2026-06-01, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07562152 (Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor Immuneering Corporation." https://clinicaltrials.gov/study/NCT07562152
- SEC Form 8-K (accession 0001790340-26-000059): "•In mid-2026, dosing the first patient in a pivotal Phase 3 clinical trial of atebimetinib in combination with mGnP in first-line pancreatic cancer patients (known as MAPKeeper 301), with a topline data readout expected in mid-2028." https://www.sec.gov/Archives/edgar/data/1790340/000179034026000059/imrx-20260601.htm
- Press release filed with the SEC (EX-99) (accession 0001790340-26-000095): "This strong momentum enables us to expand the enrollment target and potentially accelerate our expected mid-2028 topline data readout." https://www.sec.gov/Archives/edgar/data/1790340/000179034026000095/imrx-20261029xexx991.htm

## Same indication

- [RASONQUE (daraxonrasib)](https://sec-api.dev/pdufa/daraxonrasib) (RVMD)
- [N-803](https://sec-api.dev/pdufa/n-803) (IBRX)
- [RMC-6236](https://sec-api.dev/pdufa/rmc-6236) (RVMD)
- [JAKAFI (ruxolitinib)](https://sec-api.dev/pdufa/ruxolitinib) (INCY)
- [Zoldonrasib](https://sec-api.dev/pdufa/zoldonrasib) (RVMD)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/atebimetinib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Atebimetinib PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/atebimetinib

```bibtex
@misc{secapidev_pdufa_atebimetinib_20261116,
  title        = {Atebimetinib PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/atebimetinib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_atebimetinib_20261116","title":"Atebimetinib PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/atebimetinib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
